Indications
Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
Composition
- Active substance
- retigabine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Trobalt
- Active substance
- retigabine
- ATC code
- N03AX21
- Group
- Nervous system
- Therapeutic area
- Epilepsy
- Marketing authorisation holder
- Glaxo Group Limited
- Status
- Withdrawn